Print this page    •   Back to Web version of article

Next Single-Pill HIV Treatment Approved, and It's Not Called "B-Tripla"

By Paul E. Sax, M.D.

August 11, 2011

One famous HIV clinician/clinical researcher likens co-formulated TDF/FTC/EFV (Atripla) to a "Godzilla," so dominant has the treatment become as initial therapy for HIV. He bases his comments on this study done at his institution, showing that in 2007, fully 85% of patients starting treatment in their clinic began TDF/FTC/EFV.

Does this big lizard of a regimen now have a competitor? Maybe:

On August 10, 2011, FDA approved Complera, a fixed dose combination (FDC) drug product containing emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) for the treatment of HIV. The recommended dose of CompleraTM is one tablet, containing 200mg/25mg/300mg of FTC/RPV/TDF, once daily, taken orally with a meal.

A couple of quick thoughts as I get used to the name:

Isn't it odd that pronunciation of these new drugs is often a mystery? I'm still not sure whether it's etra-VIR-ine or e-TRA-virine, IN-telence or In-TEL-ence, and is "Edurant" pronounced EE-durant or EH-durant or ee-DUR-ant?

As for Complera, I'll assume the accent is on the second syllable until I hear otherwise.

Paul Sax is Clinical Director of Infectious Diseases at Brigham and Women's Hospital. His blog HIV and ID Observations is part of Journal Watch, where he is Editor-in-Chief of Journal Watch AIDS Clinical Care.

This article was provided by Journal Watch. You can find this article online by typing this address into your Web browser:

General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.